Authorization

Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum

SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- DarA© Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, womena??s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2018 BIO Investor Forum on Wednesday, October 17, 2018 at 3:00 p.m. Pacific Time. Ms. Johnson will present a DarA© overview and provide an update on the Companya??s portfolio programs.
The presentation will be webcast live and may be accessed by visiting DarA©a??s website at https://ir.darebioscience.com. A replay of the webcast will be available for 10 business days.About DarA© BioscienceDarA© Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womena??s reproductive and sexual health. The companya??s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.DarA©a??s product portfolio includes two potential first-in-class candidates currently in clinical development: OvapreneA®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as ViagraA®. To learn more about DarA©a??s full portfolio of womena??s health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.DarA© may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (https://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts.A  DarA© uses these channels to communicate with its investors and the public about the company and other issues. The information DarA© posts on its investor relations website may be deemed to be material information. DarA© encourages investors, the media, and others interested in the company to review the information DarA© posts on its investor relations website.Contacts:Investors on behalf of DarA© Bioscience, Inc.:
Ami Bavishi
Burns McClellan
abavishi@burnsmc.com
212-213-0006ORMedia on behalf of DarA© Bioscience, Inc.:
Amanda Guisbond
Canale Communications
amanda@canalecomm.com
781-405-8775Source: DarA© Bioscience
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031